D-1514-2016 Class II Terminated

Recalled by Sandoz Inc — Princeton, NJ

FDA drug recall D-1514-2016 was initiated by Sandoz Inc on Aug 24, 2016 and is designated Class II. Reason for recall: Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that product sterility may be compromised. The recall status is terminated (terminated Jul 12, 2017). Affected quantity: a) 1,584 cartons; b) 62,170 vials.

Recall details

Product Type
Drugs
Report Date
Sep 28, 2016
Initiation Date
Aug 24, 2016
Termination Date
Jul 12, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
a) 1,584 cartons; b) 62,170 vials

Product description

Phenylephrine HCI Injection, USP, 10mg/mL, packaged in a) 5 mL Vial, 50 mg/5 mL (NDC 66758-016-03), 25 x 5 mL Vials per carton (NDC 66758-016-04) and b) 10 mL Vials, 100 mg/10 mL (NDC 66758-017-01), Rx only, Manufactured for: Sandoz Inc., Princeton, NJ 08540.

Reason for recall

Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that product sterility may be compromised.

Distribution pattern

Nationwide and Puerto Rico

Code information

Lot #: a) 091914, Exp 09/16; b) 080114, Exp 08/16; 090414, 092614, Exp 09/16

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1514-2016
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1514-2016. Report a data issue: hello@regdatalab.com.